n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, March 7th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Sitestar Corp. (SYTE)

Nebula Stocks, Barchart, OTC Markets, Stockhouse and InvestorsHub reported on Sitestar Corp. (SYTE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sitestar Corp., along with its subsidiaries, engages in a number of business activities. These include asset management, acquiring and managing Heating, Ventilating, and Air Conditioning (HVAC) companies in the Southwest, offering consumer and business-grade internet access, and managing a real estate portfolio. Established in 1999, Sitestar has its corporate office in Richmond, Virginia. The Company lists on the OTCQB.

Sitestar’s corporate philosophy is to centralize capital allocation decisions at the corporate level and decentralize operational decisions among subsidiary managers.

Sitestar’s Internet Operations are managed under Sitestar.net. Sitestar.net offers consumer and business-grade internet access, wholesale managed modem services, Web hosting, and different ancillary services to customers in the U.S. and Canada.

Concerning real estate, Sitestar owns a real estate investment portfolio. This portfolio includes residential properties, vacant land, as well as one commercial property. The Company’s real estate portfolio is mainly centered in the Roanoke and Lynchburg areas of Virginia.

In June of 2016, Sitestar announced the creation of the HVAC Value Fund LLC along with JNJ Investments. Sitestar committed an initial $1 million investment to the HVAC Value Fund for acquiring and managing HVAC companies in Arizona and across the Southwest.

In May of 2017, Sitestar announced an agreement between Sitestar's Asset Management subsidiary, Willow Oak Asset Management, LLC, and the General Partner of Bridge Reid Fund I, LP to provide Bridge Reid with fund advisory services. Bridge Reid will continue to be managed by its General Partner members, Mr. Michael Bridge and Mr. Nathan Reid. Bridge Reid Funds, I, LP is a private hedge fund for accredited investors. It uses value-oriented investment principles.

In July of 2017, Mr. Keith Smith and Willow Oak Asset Management announced the launch of a private investment partnership called the Bonhoeffer Fund, LP. The Bonhoeffer Fund's portfolio is managed by Mr. Smith with administrative support provided by Willow Oak Asset Management, which is a subsidiary of Sitestar (SYTE). Mr. Smith will employ a long-only, concentrated, value-oriented strategy with an emphasis on international securities of companies with market capitalizations of $100 million to $500 million.

Sitestar Corp. (SYTE), closed Wednesday's trading session at $0.12, up 9.09%, on 383,200 volume with 7 trades. The average volume for the last 60 days is 166,834 and the stock's 52-week low/high is $0.07/$0.12.

DanDrit Biotech USA, Inc. (DDRT)

GuruFocus and MarketWatch reported on DanDrit Biotech USA, Inc. (DDRT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A development stage company, DanDrit Biotech USA, Inc.’s dedication is to develop the world’s first vaccine against colorectal cancer. The Company is engaged in development and clinical drug trials for a polytopic dendritic cell vaccine cancer immunotherapy for cancer survivors to prevent recurrence. DanDrit’s expertise in producing dendritic cells from a patient's blood is combined with conventional production methods with the goal of making new and advanced vaccines for cancer patients. DanDrit Biotech is based in New York, New York and has a presence in Denmark.

DanDrit has its Strategic Alliance strategy. The Company has built a strong pipeline of dendritic-cell-based cancer therapies. These address 40 percent of all cancer-related deaths.

DanDrit’s intention is to work with strategic partners to strengthen the in-house pipeline. The Company controls vital technologies with relevance outside its core business area. The Company may out-license or co-develop these with suitable partners.

The ability of dendritic cells to provoke a strong immune response is the basis of the vaccine therapies under development at DanDrit Biotech USA. MelCancerVac® (MCV) is a new product by the Company for colorectal cancer.

MVC uses a vaccination treatment program in addition to the customary treatment types of chemotherapy and surgery. MCV is a dendritic cell vaccine that could strengthen the immune response in colorectal cancer patients.

MelCancerVac® utilizes a patient’s own dendritic cells filled with tumor antigens from the lysate of a specifically selected melanoma cell line. MelCancerVac® has been tested in clinical trials for the treatment of two different types of cancer. One is colorectal cancer (CRC) and the other is non-small-cell lung cancer (NSCLC).

DanDrit uses a patient’s own dendritic cells, taken from the blood and loaded with tumor antigens. The dendritic cells then undergo injection back into the cancer patient. There, surface expressed antigenic peptides are recognized by T lymphocytes. T lymphocytes are stimulated by the dendritic cells to proliferate and differentiate into effecter cells that target and destroy tumor cells specifically.

DanDrit Biotech USA’s therapeutic cancer vaccine is employed either as separate treatment or complementary to other types of treatment. This includes surgery, chemotherapy, as well as radiotherapy. Furthermore, the Company has developed methods to produce tolerance-promoting dendritic cells for use in the treatment of autoimmune disease.

CRC clinical trials include Phase I at Gentofte Hospital, Denmark (Completed); Phase II at Gentofte Hospital, Denmark (Completed); and Phase II at the National Cancer Centre, Singapore (Completed). NSCLC clinical trials include Phase II at Herlev Hospital, Denmark (Completed).

Last week, DanDrit Biotech USA announced the appointment of Ambassador Mark R. Dybul, MD and Steven G. Deeks, MD to the Company’s Scientific Advisory Board. Ambassador Dybul will also serve as the Chairman of the Scientific Advisory Board.

Since 2004, Ambassador Dybul has served as Deputy Chief Medical Officer of the President’s Emergency Plan for AIDS Relief, or PEPFAR. Dr. Steven G. Deeks is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF). He is also a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital.

DanDrit Biotech USA, Inc. (DDRT), closed Wednesday's trading session at $6.15, up 2.50%, on 3,070 volume with 5 trades. The average volume for the last 60 days is 14,144 and the stock's 52-week low/high is $1.05/$7.10.

Nutra Pharma Corp. (NPHC)

UndiscoveredEquities, Pumps and Dumps, Wallstreetlivechat, Innovative Marketing, StocksToBuyNow, PennyStocks24, Serious Traders, Streetwise Reports, MyBestStockAlerts, BUYINS.NET, and Winston Small Cap reported previously on Nutra Pharma Corp. (NPHC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nutra Pharma Corp. is a biotechnology company based in Coral Springs, Florida. It specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company is marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market. Nutra Pharma lists on the OTCQB.

Nutra Pharma offers a number of drug products for sale for pain treatment. One is Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Another is Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. In addition, the Company has its Pet Pain-Away. This is the first OTC product to treat pain in companion animals without side effects.

The Company, via its subsidiaries, carries out basic drug discovery research and clinical development. The focus of its approach to drug discovery and the development of new therapeutic agents are based on specialized receptor-binding proteins found in nature, particularly those found in snake venom from the cobra. Nutra Pharma’s leading drug candidates are RPI-78M and RPI-MN.

Nutra Pharma also looks for strategic licensing partnerships to lessen the risks associated with the drug development process. The Company’s holding, ReceptoPharm, is developing technologies to produce drugs for HIV and MS.

Nutra Pharma’s subsidiary, Designer Diagnostics, engages in the research and development (R&D) of diagnostic test kits designed to be used for the fast identification of infectious diseases. These include Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma's MS drug RPI-78M was earlier granted Orphan Status by the Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis. Its RPI-MN inhibits the entry of numerous viruses known to cause severe neurological damage in diseases such as encephalitis and AIDS.

RPI-MN is undergoing development initially for the treatment of HIV. The Company’s RPI-78M is undergoing development for the treatment of multiple sclerosis (MS). RPI-78M can be administered orally, which is a first for a biologic MS drug.

Nutra Pharma is collaborating with the International Security Group. This collaboration is to investigate the use of its technology as a counter measure against nerve agents.

Furthermore, Nutra Pharma launched Luxury Feet. This is a new version and packaging of its OTC pain drug Nyloxin. Luxury Feet is specifically marketed for the treatment and prevention of pain and discomfort that women experience from wearing high heels.

Recently, Nutra Pharma announced that it partnered with EuroAmerican IP, LLC to distribute its Nyloxin® Topical Gel via the Federal Supply Schedule (FSS). The successful addition to FSS will make the product available for purchase through the US - General Services Administration (GSA Advantage) website at www.gsaadvantage.gov.

Last month, Nutra Pharma announced it filed a new provisional patent to protect its intellectual property (IP) surrounding its development of nerve agent counter measures.

Nutra Pharma Corp. (NPHC), closed Wednesday's trading session at $0.0035, up 6.06%, on 14,455,361 volume with 78 trades. The average volume for the last 60 days is 36,743,189 and the stock's 52-week low/high is $0.0004/$0.0084.

BioSig Technologies, Inc. (BSGM)

DreamTeamNetwork, SeeThruEquityResearch, Stock News Now, ResearchOTC, StockRockandRoll, Wall Street Resources, The Wall Street Transcript, Goldman Small Cap Research, PennyStockLocks, Stock Commander, Pumps and Dumps, and BUYINS.NET reported earlier on BioSig Technologies, Inc. (BSGM), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

BioSig Technologies, Inc. is a medical device company developing PURE EP™ . This is a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures. BioSig’s objective is to seek Food and Drug Administration (FDA) 510(k) approval for the PURE EP™ System. It is preparing to commercialize the PURE EP™ System. The Company has an office in Los Angeles, California focused on research and development (R&D). BioSig Technologies is based in Minneapolis, Minnesota.

The Company’s PURE EP™ is a next-generation surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system. The design of it is to help electrophysiologists in making clinical decisions in real-time through acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data that may be used to guide the electrophysiologists in identifying ablation targets (areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia)).

BioSig Technologies’ plan is to transition from pre-clinical evaluation of the PURE EP to product development. The Company expects to fully develop a Quality Management System. It signed a product development collaboration agreement with expert Mayo Clinic cardiac electrophysiologists.

The Company has attained proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center. It has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, it is collaborating with other prestigious cardiac arrhythmia centers. These include Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio, and Mount Sinai Medical Center in New York.

Furthermore BioSig Technologies has expressed its intention to enter the developing field of bioelectric medicine. In addition, it has partnered with Minnetronix on technology development. BioSig is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.

Earlier in January, BioSig Technologies announced that it has partnered with Mr. Charles Austin and JK Advisors. This is to scale up operational activities ahead of the commercial launch of the PURE EP™ System.

Mr. Austin brings to BioSig Technologies more than 25 years of experience in medical devices, pharmaceuticals, and consumer products. He most recently served as Corporate Vice President, Global Supply Chain at Johnson & Johnson, and was a member of the J&J Management Committee.

At present, Mr. Austin serves on numerous boards in the medical and consumer spaces. He is a Principal in JK Advisors, which is a San Diego, California based firm centered on the medical space.

BioSig Technologies, Inc. (BSGM), closed Wednesday's trading session at $1.44, up 1.41%, on 24,341 volume with 47 trades. The average volume for the last 60 days is 36,798 and the stock's 52-week low/high is $1.20/$2.00.

STG Group, Inc. (STGG)

InvestorsHub, The Stock Rover, and PoliticsAndMyPortfolio reported on STG Group, Inc. (STGG), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Formed in 1986, STG Group, Inc. is a top provider of mission-critical technology, cyber, and data solutions to the U.S. Government. The Company works to ensure the security of the digital domain, the effectiveness of complex Information Technology (IT) systems, and the delivery of quality intelligence to decision makers.

STG Group has its corporate headquarters in Reston, Virginia. It has offices in Arlington, Virginia; North Charleston, South Carolina; and Sierra Vista, Arizona. The Company formerly went by the name Global Defense & National Security Systems, Inc. It changed its name to STG Group, Inc. in November 2015. The Company’s shares trade on the OTC Markets Group’s OTCQB.

STG provides performance-oriented solutions in cyber security and secure information systems, software development, systems and services and intelligence and analytics. The Company has expanded its core competencies. Some of its key projects have included engineering solutions for fast prototyping and battlefield support, development of unique name searching algorithms for six language families, and niche scientific solutions for specialized agency missions.

The Company’s solutions are vital to national security-related programs and day-to-day operations across more than 50 U.S. government agencies. STG serves its customers at greater than 250 locations domestically and worldwide. STG was one of the first small companies to receive an ISO 9001:2008 certification and an SEI CMMI Maturity Level 3 rating.

Pertaining to Intelligence and Analytics, the Company’s experts gather data from numerous sources, analyze and fuse the data to provide clarity and situational context, and disseminate the resulting intelligence to a diverse range of stakeholders.

Regarding Cyber Security and Secure Information Systems, STG Group’s mission is to establish, develop, and sustain secure, resilient, enterprise level information systems.

Concerning Software Development, Systems and Services, STG’s agile software development practices scale to system demands. This ranges from iterative system builds to highly integrated enterprise platforms.

STG Group serves its customers at over 250 locations domestically and internationally. Its corporate mission is to provide premier technical and professional services solutions, which enable the success of its customers’ missions.

STG Group, Inc. (STGG), closed Wednesday's trading session at $0.355, down 22.83%, on 10,575 volume with 7 trades. The average volume for the last 60 days is 30,375 and the stock's 52-week low/high is $0.008/$3.75.

BioVie, Inc. (BIVI)

Wealth Insider Alert reported previously on BioVie, Inc. (BIVI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of inventive drug therapies for liver disease. Currently, the clinical-stage Company is concentrating on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. BioVie has its corporate headquarters in Beverly, Massachusetts. The Company’s shares trade on the OTCQB.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in approximately 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States.

BioVie states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering the Company’s new drug candidate BIV201.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The FDA has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at over $4 billion per year.

In April 2017, BioVie announced that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 may begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis.

Furthermore, the Company was notified by the USPTO that its application for a core patent covering the use of BIV201 to lessen ascites formation in ambulatory patients was authorized.

Additionally, BioVie announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

In November 2017, BioVie reported that a second patient was dosed with the Orphan drug candidate BIV201 (continuous infusion terlipressin) in a mid-stage Phase 2a clinical trial of patients suffering from refractory ascites due to advanced liver cirrhosis. The design of the study is to evaluate 6 patients with refractory ascites. In October 2017, the first patient completed 28 days of treatment with BIV201 and entered the post-therapy observational period.

This past December, BioVie announced that the FDA granted Fast Track designation for BIV201 (continuous infusion terlipressin), the Company's patented Orphan drug candidate. BIV201 is now undergoing evaluation for the treatment of refractory ascites due to liver cirrhosis in a mid-stage (Phase 2a) US clinical trial, with two of the planned six patients having been treated with this therapy so far. The results for all six refractory ascites patients planned for the Company’s Phase 2a clinical trial of BIV201 are expected by Q2 of 2018.

BioVie, Inc. (BIVI), closed Wednesday's trading session at $0.05005, up 138.33%, on 295,677 volume with 37 trades. The average volume for the last 60 days is 35,012 and the stock's 52-week low/high is $0.0207/$0.45.

Patriot Gold Corp. (PGOL)

OtcWizard, Gold Investment Letter, Real Pennies, and Standout Stocks reported previously on Patriot Gold Corp. (PGOL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Patriot Gold Corp. is a precious metals exploration and production company. Its mission is to discover and develop significant gold and silver assets in the States of Arizona and Nevada. At present, the Company holds a portfolio of four projects. These are the Moss project in Arizona and three in Nevada (Bruner, Vernal, and Windy Peak). Patriot Gold has its corporate office in Las Vegas, Nevada.

The Company holds a 3 percent royalty in the Moss Mine in Arizona, an interest in the Bruner gold project in Nevada, and a 100 percent interest in the Vernal and Windy Peak projects in Nevada.

The Moss Mine Project is within the historic Oatman District, 10 miles east of Bullhead City, Arizona and around 70 miles southeast of Las Vegas. The Moss Mine is owned by Northern Vertex Mining Corp.

The Bruner gold project property is roughly 130 miles east-southeast of Reno, Nevada. It is at the northern end of the Paradise Range and 45 miles northwest of the Round Mountain Mine. Patriot Gold owns a 2 percent royalty in the Bruner gold project. The Bruner gold project is owned by Canamex Resources Corp.

The Windy Peak Gold Project consists of 79 unpatented mineral claims in the Fairview mining district in southwest Nevada. Windy Peak is easily accessed. It is approximately 45 miles southeast of Fallon and 6 miles from Middlegate.

The Vernal gold project is in its early stage. The property is approximately 140 miles east-southeast of Reno, Nevada, on the west side of the Shoshone Mountains. The property consists of 12 unpatented mining claims (240 acres).

The Bruner and Vernal gold projects are in Nevada's Walker Lane, which hosts numerous major deposits. These include the Goldfield (greater than 5 million ounces of post production and present reserves) and the Comstock (greater than 8 million ounces).

Last month, Patriot Gold reported that the Moss Mine, owned by Northern Vertex Mining, is quickly advancing toward the pouring of its initial commercial gold/silver dore bars, according to a recent announcement by Northern Vertex. Northern Vertex Mining announced that around 7,800 tons of ore were stacked on the pad so far.

Northern Vertex is moving towards an initial stacking rate of 2,500 tpd, and subsequently to 5,000 tpd. Additionally, it reported that all of the crushing plant components were tested and commissioned, piping on the heap leach pad started, and the refinery furnace was to be commissioned.

In addition, in February, Patriot Gold announced that permitting is in place for its 2018 drilling program on its Windy Peak gold project in Nevada. The Company has identified a number of drilling targets. Patriot is in the process of choosing a drilling contractor.

Patriot Gold Corp. (PGOL), closed Wednesday's trading session at $0.0805, down 0.12%, on 3,700 volume with 1 trade. The average volume for the last 60 days is 38,706 and the stock's 52-week low/high is $0.045/$0.128.

RenovaCare, Inc. (RCAR)

Insider Financial, Zacks, and MarketWatch reported on RenovaCare, Inc. (RCAR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company’s first product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for fast self-healing.

RenovaCare is based in New York, New York and the Company lists on the OTCQB. It previously went by the name Janus Resources, Inc. It changed its name to RenovaCare, Inc. in January of 2014.

The Company’s flagship technology, the CellMist™ System, utilizes its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, as well as scars.

The CellMist™ System targets patients around the world who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo. RenovaCare’s approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds was validated by researchers in ‘Differentiation’, a leading peer-reviewed scientific publication. According to their findings, the methodology that has been adopted by RenovaCare successfully isolates those specific cell populations with the greatest regenerative capacity to support the growth of fully-functioning skin.

In investigative clinical use in the United States SkinGun™ treatments have shown the potential to naturally and quickly heal burns and other serious wounds. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering an emergency room. A patient’s stem cells are isolated, processed, and sprayed onto wound sites for rapid healing.

Skin stems cells sprayed with the Company’s patented SkinGun™ device maintain 97.3 percent cell viability. There is no impairment to cell growth or metabolic activity when evaluated in vitro. The SkinGun™ is now on display at the prestigious Science Museum in London (founded in 1857).

RenovaCare has a partnership to validate the science behind its innovative technology for treatments of wounds, burns, and other skin defects. The Company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT). This is a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals.

In 2017, RenovaCare had studies in prestigious journals. In addition, the Company miniaturized the SkinGun™ from the size of a microwave to a device that fits comfortably in one hand.

To date, as of January 9, 2018, 72 patients have been treated, with 45 in Pittsburgh, Pennsylvania, and 27 in Berlin, Germany. Nineteen of the Berlin patients were treated with an early prototype of RenovaCare’s SkinGun™.

The next significant milestone for the Company will be its initial Food and Drug Administration (FDA) filing. The FDA filing will advance RenovaCare’s pioneering technology towards market. Its initial FDA filing will be to demonstrate the safety and efficacy of its approach for treating wounds employing a patient’s own skin cells.

RenovaCare, Inc. (RCAR), closed Wednesday's trading session at $6.44, up 11.42%, on 141,902 volume with 468 trades. The average volume for the last 60 days is 189,625 and the stock's 52-week low/high is $2.30/$12.85.

Thunder Mountain Gold, Inc. (THMG)

Zacks, FeedBlitz, and MarketWatch reported on Thunder Mountain Gold, Inc. (THMG), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Thunder Mountain Gold, Inc. is a junior gold exploration company headquartered in Boise, Idaho. The Company owns interests in numerous United States precious metals projects. Its chief asset is The South Mountain Project. The South Mountain Project is on private and patented land in southern Idaho, just north of the Nevada border. Formed in 1935, Thunder Mountain Gold lists on the OTC Markets’ OTCQB.

Another important asset of the Company is the Trout Creek Project. The Trout Creek target is in the Reese River Valley area south of Battle Mountain, Lander County, Nevada.

This is a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, now under Joint Exploration Agreement with Newmont USA Limited. This target consists of 60 unpatented lode mining claims.

Trout Creek is on an important trend with Newmont's Phoenix Mine and the Gold Acres, Pipeline. The Cortez Mine sits to the southeast.

Thunder Mountain Gold signed an Amendment, which modifies and extends the exploration Minerals Lease and Agreement with Newmont USA Limited on the Trout Creek Project. The extension allows it more time to complete work requirements on the project and reduces the yearly work obligations.

Thunder Mountain Gold’s other projects include Clover Mountain. The Company controls 40 unpatented lode mining claims covering about 800 acres, near Clover Mountain in Owyhee County, Idaho. In addition, the Company’s West Tonopah Property consists of 8 unpatented lode mining claims totaling 160 acres in the Tonopah Mining District, Esmeralda County, Nevada.

Thunder Mountain Gold owns 100 percent of the aforementioned South Mountain Mine. This mine has a land package comprising approximately 1,200 acres of mostly private land - both owned outright and leased. In 2009, a new gold discovery was revealed during fieldwork at South Mountain. The Company’s plan of operation for this, subject to business conditions, is to continue to advance the development at the South Mountain Project.

In fact, the South Mountain Project remains Thunder Mountain Gold’s focus. The flagship South Mountain Project was initially mined in the late 1800s. The primary metals at South Mountain are silver, zinc, lead, copper, and gold.

The South Mountain Mine property was mined underground extensively during World War II. Smelter records for direct ship from the mine during the periods 1940 through 1954 showed a total of 53,642 tons of ore that contained 15,593,000 pounds of zinc (14.5 percent), 2,562,300 pounds of lead (2.4 percent), 1,485,200 pounds of copper (1.4 percent), 566,439 ounces of silver (10.6 ounces per ton)(opt) and 3,120 ounces of gold (0.058 opt).

Thunder Mountain Gold, Inc. (THMG), closed Wednesday's trading session at $0.20, even for the day. The average volume for the last 60 days is 5,954 and the stock's 52-week low/high is $0.075/$0.30.

Atacama Resources International, Inc. (ACRL)

MarketWatch and OTC Markets reported on Atacama Resources International, Inc. (ACRL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Atacama Resources International, Inc. has significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, diamonds, graphite and cobalt. Furthermore, major deposits of copper and iron ore are included in the mining claims. Atacama Resources International is headquartered in Plantation, Florida.

Regarding Minerals, the Company has numerous claims on 4460 acres in the Kirkland Lake and other areas of mineral-rich northern Ontario. The Company’s initial line of business is a combination of mining, acquisition, as well as development of mining interests in the Kirkland Lake region.

Atacama Resources International announced last September that it engaged Canadian Exploration Services Ltd. (CXS) to conduct a geological evaluation of the Company’s Cabo property. The Cabo property comprises Mining Claim 4225513, located in the Township of Lorrain in the heart of all the high-profile cobalt activity surrounding the historic mining town of Cobalt, Ontario.

Atacama Resources has acquired the mineral rights for the Mystery Graphite Property that comprises 1740 acres situated roughly 60 miles south of Timmins, Ontario. The acquisition of the mineral rights includes receiving core samples collected from numerous diamond drill sites earlier conducted on the property

Additionally, Atacama Resources is involved in a new line of business that it states will make the highways of the U.S. and Canada safer and saves lives in the process. The Company, as part of its expansion portfolio, acquired Good2Drive™, Inc. Good2Drive, Inc. is a wholly-owned subsidiary of Atacama Resources International.

Good2Drive™ is an entity that has the rights to an application (app), which detects levels of cognitive awareness and reports those levels in accordance with the users' demands and needs. The Company’s technology business includes the innovative Smartphone application Good2Drive and also follow on products that will be released this year.

Atacama Resources International released Good2Drive in 2017. Good2Drive is a mobile application that enables drivers, corporate fleets, and law enforcement to test a driver's cognitive alertness before getting behind the wheel of a motor vehicle. Good2Drive uses a 60-90 second image matching test using a patented algorithm that was created based on the scientific study of cognitive abilities at different West Coast hospitals and universities.

Good2Drive’s dedication is to providing Smartphone hosted applications founded on its proprietary testing for cognitive awareness. Its set of Smartphone hosted apps will include cognitive tests for care givers, seniors with impairments, remote employees in potentially hazardous environments, and other situations where it is necessary to be cognitively alert.

Atacama Resources International also has its Good2Drive/Fleet. This is a mobile application. It enables commercial fleet owners and operators to manage manifold drivers as they test their mental alertness before getting behind the wheel of a vehicle.

This past December, Atacama Resources International announced that it released ‘Fit4Duty’. This is a mobile application that permits companies to test cognitive alertness for its employees before getting behind the wheel of a company vehicle and for employees working in potentially hazardous work assignments. Fit4Duty includes a 60-90 second image matching test utilizing a patented algorithm.

Atacama Resources International, Inc. (ACRL), closed Wednesday's trading session at $0.00075, down 6.25%, on 6,030,950 volume with 23 trades. The average volume for the last 60 days is 55,188,981 and the stock's 52-week low/high is $0.0005/$0.52.

First Choice Healthcare Solutions, Inc. (FCHS)

007 Stock Chat, PennyStockSpy, Greenbackers, StocksImpossible, TheMicrocapNews, First Penny Picks, Marketbeat, and OTCBB Journal reported on First Choice Healthcare Solutions, Inc. (FCHS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

First Choice Healthcare Solutions, Inc. (FCHS) engages in owning and operating multi-specialty (non-physician-owned) medical centers of excellence throughout the southeastern United States. The Company is one of the nation's only non-physician-owned, publicly traded healthcare services enterprises centered on the delivery of total musculoskeletal solutions with a concentration on Orthopaedic and Spine care. FCHS has its head office in Melbourne, Florida.

The Company’s devotion is to deliver clinically superior, patient-centric care. Its flagship integrated platform currently administers greater than100,000 patient visits annually. It consists of First Choice Medical Group, The B.A.C.K. Center, and Crane Creek Surgery Center.

FCHS medical centers of excellence focus on treating patients in different specialties. These include Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management, as well as related diagnostic and ancillary services.

First Choice Medical Group (Melbourne, Florida) is the Company’s flagship multi-specialty medical center of excellence. First Choice Medical Group specializes in the delivery of musculoskeletal medicine and rehabilitative care with manifold quality-focused goals focused on enriching its patients’ care experience.

FCHS has expanded its portfolio of Medical Centers of Excellence in the Florida Space Coast region, with its Brevard Orthopaedic Spine & Pain Clinic, Inc., dba The B.A.C.K. Center. The B.A.C.K. Center is a leading, advanced orthopaedic spine and pain practice in Brevard County, Florida. Its emphasis is on Spinal Care & Surgery; Non-Operative Spine Procedures; Chiropractic Services; Osteoporosis Care; Acupuncture; and Interventional Pain Management.

FCHS’s Crane Creek Surgery Center is an AAAHC accredited facility. Its dedication is to deliver first-rate, ambulatory surgical care in a convenient, comfortable outpatient environment. The 18,000-plus sq. ft. facility is in Melbourne, Florida within the Crane Creek Medical Center building. This building is also home to The B.A.C.K. Center.

In February, FCHS announced that one of its wholly-owned subsidiaries, CCSC Holdings, Inc. acquired an additional 25 percent ownership interest in Crane Creek Surgery Center. This brings its total ownership interest to 65 percent. Furthermore, CCSC Holdings has assumed management responsibility of Crane Creek and ended the earlier agreement with NueHealth.

Last week, FCHS announced the closing of its strategic partnership with Steward Health Care System. Steward is the largest private hospital operator in the U.S. This closing was formalized with Steward Health Care System’s investment of $7.5 million in exchange for 5 million shares of FCHS stock.

Mr. Chris Romandetti, FCHS’ President and Chief Executive Officer, stated, "The finalization and closing of this strategic partnership with Steward provides excellent momentum for all parties involved. An investment of this magnitude allows First Choice to expeditiously continue to rollout our unique and proven delivery platform among Steward’s nationwide network….”

First Choice Healthcare Solutions, Inc. (FCHS), closed Wednesday's trading session at $1.38, down 0.72%, on 7,200 volume with 14 trades. The average volume for the last 60 days is 14,395 and the stock's 52-week low/high is $0.90/$1.63.

graphic

The QualityStocks
Company Corner

graphic
graphic

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0698, up 14.43%, on 8,450,794 volume with 522 trades. The stock’s average daily volume over the past 60 days is 9,683,335, and its 52-week low/high is $0.0132/$0.415.

SinglePoint Inc. (OTCQB: SING) is pleased to announce the soft launch of its SingleSeed payment bitcoin payments solution. Additionally, SinglePoint management provides details and insight to the company's activity in new ventures and pursuit of acquisitions in two major emerging markets: cannabis and blockchain.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Launches Cannabis Payment Solution and Provides Shareholder Update

SinglePoint, Inc. (SING) Blockchain-related Applications Gain Momentum

SinglePoint Looks to Apply Blockchain to Healthcare with New LOI -- CFN Media

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.028, up 9.35%, on 6,793,615 volume with 313 trades. The stock’s average daily volume over the past 60 days is 15,248,879 and its 52-week low/high is $0.0181/$0.0728.

Cannabis Strategic Ventures, Inc. (OTC: NUGS) and Marijuana Company of America Inc. (OTC: MCOA) announced the signing of staffing agreement between the two companies today.

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Cannabis Strategic Ventures (NUGS) and Marijuana Company of America (MCOA) Managing Growth With New Staffing Contract

Marijuana Company of America Inc. (MCOA) Expands hempSMART™ Product Line with New Pet Products

CannabisNewsBreaks – Marijuana Company of America, Inc. (MCOA) Offers Hemp-based CBD Products through its hempSMART Line

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.57, up 10.93%, on 661,551 volume with 625 trades. The stock’s average daily volume over the past 60 days is 72,040, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSXV: PQE; OTCQX: PQEFF; Frankfurt: A2DYWC), a company focused on the development and implementation of proprietary technologies for the energy industry, is pleased to announce that SOCAR Energy Ukraine, Ltd. (“SOCAR”), a subsidiary of State Oil Company of Azerbaijan Republic, as the latest member of PetroBLOQ, the Company’s subsidiary and developer of a blockchain-based oil and gas supply chain management platform.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Azerbaijan Oil Major SOCAR Energy (Ukraine Branch) Joins Petrobloq's Oil & Gas Blockchain-Based Consortium

Petroteq Energy Announces Offtake Agreement With Firebird Logistics for 100% of Production From Its Utah Heavy Oil Extraction Facility

Petroteq Energy Announces Completion of All Major Process Systems at Its Utah Heavy Oil Extraction Facility

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.52, up 2.70%, on 77,112 volume with 153 trades. The stock’s average daily volume over the past 60 days is 128,657, and its 52-week low/high is $0.47/$2.70.

EVIO, Inc. (OTCQB: EVIO), a life sciences and cannabis testing company, this morning said that it has recently invested $800,000 in new equipment upgrades at its EVIO Labs Massachusetts facility and its EVIO Labs Colorado licensee.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

NetworkNewsBreaks – EVIO, Inc. (EVIO) Invests $800,000 in New Laboratory Equipment at Two Cannabis Testing Facilities

EVIO, Inc. (EVIO) Continues to Improve, Expanding EVIO Cannabis Testing Lab Services, Locations

EVIO, Inc. (EVIO) Sets Up in California as July 2018 Mandatory Cannabis Testing Deadline Approaches

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.40, up 2.94%, on 89,278 volume with 136 trades. The stock’s average daily volume over the past 60 days is 407,634 and its 52-week low/high is $0.27/$2.54.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP), a client of NNW that has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. To view the full publication, titled “Smokers Light Up Less, Alternative Nicotine Delivery Technologies Take Center Stage,” visit: http://nnw.fm/JZg2e.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication on Custom Innovations in Nicotine Delivery

Smokers Light Up Less, Alternative Nicotine Delivery Technologies Take Center Stage

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Seven-Year Licensing Agreement with Cannfections Group, Inc.

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.08, off by 0.92%, on 35,571 volume with 23 trades. The stock’s average daily volume over the past 60 days is 137,696 and its 52-week low/high is $0.20/$1.75.

ORHub, Inc. (ORHB) was noted today amid LOI associate SinglePoint’s announcement of the soft launch of its SingleSeed bitcoin payments solution, and pending acquisitions in the cannabis and blockchain markets.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

SinglePoint Launches Cannabis Payment Solution and Provides Shareholder Update

Blockchain Innovations Set to Disrupt Healthcare

SinglePoint Signs LOI with ORHub to Launch Healthcare Blockchain Initiative

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.121, off by 0.20%, on 423,126 volume with 63 trades. The stock’s average daily volume over the past 60 days is 936,762, and its 52-week low/high is $0.0045/$0.52.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Epazz, Inc. (OTC:EPAZ), a client of NNW that specializes in enterprise cryptocurrency blockchain mobile apps and cloud business process software with more than 500 repeat customers. To view the full publication, titled “Blockchain-related Applications Gain Momentum,” visit: http://nnw.fm/bmGY5.

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

NetworkNewsWire Announces Publication on Groundbreaking Innovations Utilizing the Power of Blockchain

Epazz, Inc. (OTC: EPAZ) Blockchain-related Applications Gain Momentum

Epazz ZenaPay Blockchain Bitcoin Ethereum Wallet Has Been Downloaded More Than 25,000 Times Since Launch on the Play Store, Helping to Improve Its Ranking

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF). Today, Choom Holdings Inc. closed trading at $0.606, off by 2.79%, on 149,794 volume with 127 trades. The stock’s average daily volume over the past 60 days is 57,092, and its 52-week low/high is $0.125/$0.8612.

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) was pleased to announce today that it has signed the first agreement in its retail investor program and is pleased to welcome an Okanagan consortium to the Choom™ brand. This follows Choom's announcement on January 18th, 2018 highlighting a retail strategy of developing a chain of branded retail cannabis dispensaries across Canada. Also today, CannabisNewsWire issued a report on how the Canadian cannabis industry is pliable, changing shape amid mounting public support, favorable legislative action, an influx in capital, and the integration of alcohol and tobacco. Explaining that Choom is targeting the recreational user in this market via its own brand of high-grade handcrafted cannabis.

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s "Choom Gang," a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with "choom," the local's term for marijuana. Choom's trademark slogans pivot off another unconventional phrase ("Say Hello to…"), bringing a heady dose of good times and good friends together as the company invites investors to "Say Hello to Choom™" as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company's first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom's initial license applications to ensure the company's readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company's character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1's revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic "Aloha" vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company's growth strategy. Get ready to "Say Hello" to opportunity, good times and good friends with Choom™. Disclaimer

Choom Holdings Inc. Company Blog

Choom Holdings Inc. News:

Choom™ Announces First Regional Retail Investment Group

Pliability of Canadian Cannabis Industry Triggers New Business Development

NetworkNewsBreaks – Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Receives Processing Approval from Depository Trust Company

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.3955, off by 5.81%, on 9,185,447 volume with 2,049 trades. The stock’s average daily volume over the past 60 days is 14,429,899, and its 52-week low/high is $0.0006/$0.957.

PotNetwork Holding, Inc. (OTC Pink:POTN) announced today that its wholly owned subsidiary, Diamond CBD Inc.com, achieved over $500,000 in website- generated orders, surpassing all previous online sales records.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding Inc.’s Diamond CBD Sets New Record For Monthly Online Sales with Over $500,000 in February Online Revenues Alone

PotNetwork Holding's Diamond CBD and XPO2 Unite For First Charity Drive in Manila, Philippines

PotNetwork Holding’s Diamond CBD Signs Exclusive Global Affinity Marketing Agreement with Exponential, Inc.

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF)

The QualityStocks Daily Newsletter would like to spotlight Global Hemp Group, Inc. (GBHPF). Today, Global Hemp Group, Inc. closed trading at $0.125, off by 14.38%, on 225,850 volume with 46 trades. The stock’s average daily volume over the past 60 days is 436,941, and its 52-week low/high is $0.0115/$0.316.

Global Hemp Group, Inc. (CSE:GHG) (OTC:GBHPF) is pleased to announce the closing of a non-brokered private placement, consisting of 12,500,000 units ("Units") at a price of $0.12 per Unit to raise aggregate gross proceeds of $1,500,000.

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Hemp Group, Inc. Company Blog

Global Hemp Group, Inc. News:

Global Hemp Group Announces Completion of $1.5 Million Private Placement

CannabisNewsBreaks – Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) Pursues its Share of America’s Prosperous Cannabis Industry

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) Pursuing Opportunities in America’s ‘New Billion-Dollar Crop’

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.018, off by 6.74%, on 12,670,536 volume with 321 trades. The stock’s average daily volume over the past 60 days is 12,810,068, and its 52-week low/high is $0.0141/$0.16.

Global Payout, Inc. (OTC Pink:GOHE) supply chain finance subsidiary, SecurCapital Corp today announced the appointment of its CEO to the Deliver-EZ Board of Directors a ground breaking final mile solutions company offering neighborhood robotically operated package delivery hubs open 7 by 24. Also today, NetworkNewsWire released a report on how blockchain continues to become increasingly important in the financial technology sector. And how Global Payout, Inc. (GOHE) has incorporated blockchain into payment and business consulting services for high-risk parts of the economy, as well as supply chain management.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

SecurCapital CEO joins Board of Directors of Deliver-EZ

Blockchain Integration Revives Traditional Services

MoneyTrac Technology Inc.'s Strategic Partner GreenBox POS, Sponsors Native San Diegan in Olympic Bid

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(BIVI) +138.33%

2.

StockMarketWatch
(PIXY) +66.15%

3.

Wall Street Mover
(ZSAN) +56.57%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251